| 摘要 |
<p>The invention relates in particular to a method for determining, in vitro, the specific activity of the LPA1 receptor by measuring the expression of the HBEGF and CXCL3 markers, in particular for determining, in vitro, the modulatory activity of a compound specifically with respect to the LPA1 receptor, in particular in the context of monitoring the efficacy of a therapeutic compound specifically targeting the LPA1 receptor.</p> |
